DY131, a selective ERR¦Ã agonist, could potentiate the ERR¦Ã-induced growth inhibition in LNCaP- ERR¦Ã and DU145- ERR¦Ã cells in a dose-dependent manner compared with respective parental cells. DY131 inhibited the growth of the ER¦Á-positive endometrial cancer cells but promoted that of the ER¦Á-negative cancer cells. DY131 had no effect on the structurally related receptors ERR¦Á or the estrogen receptors alpha and beta (ERalpha/beta). DY131 appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists.

June 21, 2017

prudect name : DY131, a selective ERR¦Ã agonist, could potentiate the ERR¦Ã-induced growth inhibition in LNCaP- ERR¦Ã and DU145- ERR¦Ã cells in a dose-dependent manner compared with respective parental cells. DY131 inhibited the growth of the ER¦Á-positive endometrial cancer cells but promoted that of the ER¦Á-negative cancer cells. DY131 had no effect on the structurally related receptors ERR¦Á or the estrogen receptors alpha and beta (ERalpha/beta). DY131 appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists.
DY131

Synonyms: GSK 9089;DY-131;DY 131;GSK9089;GSK-9089CAS NO: 95167-41-2Molecular Formula: C18H21N3O2Molecular Weight: 311.38Purity: 98% minSolubility: In DMSOStorage: -20°C


LGK-974 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18511747